Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Xenetic Biosciences Inc | XBIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.7759 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.7759 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.55 - 5.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.7759 | USD |
Xenetic Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.82M | 1.54M | - | 2.54M | -4.14M | -2.68 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Xenetic Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XBIO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.06 | 4.30 | 3.74 | 3.81 | 2,569 | -0.2841 | -7.00% |
| 1 Month | 3.85 | 4.74 | 3.74 | 4.34 | 6,881 | -0.0741 | -1.92% |
| 3 Months | 3.66 | 4.74 | 3.3301 | 4.16 | 5,747 | 0.1159 | 3.17% |
| 6 Months | 3.06 | 4.74 | 2.8696 | 3.86 | 5,199 | 0.7159 | 23.40% |
| 1 Year | 4.621 | 5.97 | 2.55 | 3.64 | 17,122 | -0.8451 | -18.29% |
| 3 Years | 19.60 | 56.80 | 2.401 | 29.40 | 941,726 | -15.82 | -80.74% |
| 5 Years | 14.30 | 168.895 | 2.401 | 26.49 | 746,185 | -10.52 | -73.60% |
Xenetic Biosciences Description
| Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. |
